Last Updated: 29 Jul 2025
Source: Statifacts
The US catheters market size was evaluated at USD 8.41 billion in 2024 and is expected to grow around USD 17.66 billion by 2034, registering a CAGR of 7.70% from 2025 to 2034.
| Reports Attributes | Statistics |
| Market Size in 2024 | USD 8.41 Billion |
| Market Size in 2025 | USD 9.06 Billion |
| Market Size in 2032 | USD 15.22 Billion |
| Market Size by 2034 | USD 17.66 Billion |
| CAGR 2025 to 2034 | 7.70% |
| Base Year | 2024 |
| Forecast Period | 2025 to 2034 |
Catheters are generally thin tubes made of plastic, nylon, silicone rubber, and polyvinyl chloride (PVC). It is broadly utilized in catheterization during surgical procedures such as neurosurgery and angioplasty. Demographic aging, a growing burden of chronic cardiovascular as well as renal disease, and wider acceptance of minimally invasive processes continue to provoke demand. Technology cycles that deliver embedded sensors, smarter coatings, and AI-programmed designs thus broaden the clinical utility of catheter products. Developments in catheter technology have permitted minimally invasive procedures, decreasing patient discomfort and also recovery time. Favorable reimbursement policies, mainly for minimally invasive procedures, led to market growth.
The incorporation of artificial intelligence (AI) into healthcare has provoked a paradigm shift in numerous medical disciplines, including cardiology. AI is an area of computer science aimed at creating machines or systems that can execute tasks that mainly require human intelligence. It encompasses numerous techniques that permit machines to simulate human-like behaviors such as reasoning, learning, perception, problem-solving, and decision-making. Machine learning is a part of AI that is a technique that permits machines to learn from huge training data without being explicitly programmed.
It involves the advancement of algorithms that permit computers to recognize patterns within datasets, make predictions, learn from these patterns, and/or take actions derived from the learned data. To advance medicines, researchers require an understanding of which biological as well as genetic variations cause diseases. By using AI to de-identify medical datasets, like electronic health records, genetic sequencing data, or lab results, scientists can shed light on what directly causes specific diseases.
Catheters market drivers include the growing preference for minimally invasive procedures is driving demand for versatile catheter technologies across specialties, offering patients faster recovery, reduced pain, and shorter hospital stays.
Catheters are important tools in minimally invasive surgeries, which are rousingly preferred due to their advantages for patients. Procedures such as angioplasty, where a catheter is utilized to block or open narrowed blood vessels, are becoming more common than conventional open surgeries. Catheters are utilized in a broad range of medical specialties, including urology, neurology, cardiology, and gastroenterology. The versatility of catheter technology permits its use in different procedures, thus fueling market expansion.
Examples such as cardiac catheterization for the detection and treatment of transcatheter aortic valve replacement (TAVR), heart conditions, and mitral valve repair. These procedures provide less pain, quicker recovery, and shorter hospital stays for patients.
Obstacles in the catheters market are a shortage of trained professionals and competition from alternative therapies, which may offer greater cost-efficiency or effectiveness in certain procedures.
The demand for highly skilled professionals to do catheter-driven interventions means that there is a continued need for training and education in this area. This can lead to a lack of qualified healthcare individuals, mainly in areas with restricted access to specialized training. The difficulties lie in the competition from other therapies, like embolization coils and other apparatus used in vascular surgeries. While occlusion catheters have a unique set of advantages, like higher control during procedures, alternative goods can be considered more effective and expense-efficient in a few applications.
Lucrative prospects in the XYZ market encompass sensor-enabled smart catheters are revolutionizing patient monitoring and minimally invasive care, driving investment and innovation across the medical device landscape.
Sensors embedded in catheters can offer continuous monitoring of parameters such as pressure, temperature, and flow rate, providing valuable insights into an individual's condition. Sensor-enabled catheters can help with minimally invasive procedures, decreasing patient trauma, recovery time, as well as the risk of complications. The market for sensor-derived smart catheters is attracting remarkable investment from both well-known medical device firms and startups, thus fueling innovation and growth.
"Our partnership with Abbott allows us to expand access to our advanced automated insulin delivery and smart MDI systems that deliver best-in-class outcomes with the most widely used CGM in the world," said Que Dallara, executive vice president and president, Medtronic Diabetes. "We're committed to simplifying diabetes management and making the transition to automated technology much more seamless for those who wish to achieve more with their diabetes care."
“The decision to pursue this separation was driven by our active portfolio management process and focus on driving shareholder value,” said Liam Kelly, Teleflex's Chairman, President, and Chief Executive Officer. “Following the separation, RemainCo will be well-positioned to accelerate growth in attractive, primarily hospital-focused, emergent end markets, with a simplified operating model, streamlined manufacturing footprint, and increased management focus. We expect RemainCo to have increased flexibility to invest in and better compete in the markets in which it will operate, with a focus on enhanced innovation. We believe NewCo will also emerge poised to deliver greater value via its enhanced ability to identify, invest in, and capitalize on the opportunities unique to its end markets. This transaction is designed to optimize the positioning of both companies in order to better meet the needs of patients and customers and maximize value for shareholders.”
“Drug discovery is an extremely challenging process with only a small percentage of lead compounds moving into clinical trials and an even smaller percentage becoming approved medicines,” says Chris Moy, Scientific Director, Oncology, Data Science & Digital Health, R&D, Johnson & Johnson Innovative Medicine. “By applying AI, we can advance the most promising drug candidates into clinical development, to improve the probability of successfully bringing a drug to market and rapidly getting new treatments to the patients who need them the most.”
The peripheral intravenous catheters (PIVCs) segment dominated the U.S. catheters market in 2024. PIVCs are adaptable for their usage in hospitals, emergency care, and outpatient facilities, making them a preferred choice for many procedures. Developments in safety-engineered designs have decreased risks such as needle stick injuries as well as catheter-related infections, thus raising their popularity. They are comparatively simple to insert and remove, assisting with quick venous access, especially for short-term therapies.
The central venous catheters segment is expected to be the fastest growing in the U.S. catheters market during the forecast period. CVCs are important for delivering medications, fluids, nutrition, and blood products in numerous clinical settings, including intensive care, emergencies, and long-term therapies. The rising prevalence of chronic diseases such as cancer and kidney failure, which usually require long-term vascular access, thus fuels the need for CVCs. Producers are introducing technologically developed CVCs with features such as multiple lumens, radiopaque tips, and ergonomic designs to improve performance and reduce complications.
The cardiovascular segment dominated the U.S. catheters market in 2024. The United States has a huge population with cardiovascular diseases, contributing to a high need for diagnostic and therapeutic processes using catheters. Hospitals are important centers for advanced cardiovascular care, which includes catheter-based procedures, and account for a remarkable portion of catheter use. Millions of cardiac catheterization procedures are done annually in the U.S., thus solidifying the market portion of cardiovascular catheters.
The urology segment is expected to be the fastest-growing in the U.S. catheters market during the forecast period. Innovations in catheter design, like the advancement of coated catheters and hydrophilic catheters, are improving patient comfort and lessening the risk of infections, and increased knowledge about urological health, as well as the availability of numerous treatment alternatives, including catheterization, are also responsible to a role in the market's growth. The tendency toward minimally invasive surgical procedures in urology is also leading to the increasing usage of catheters, mainly in procedures related to prostate issues and kidney stones.
The triple-lumen segment dominated the U.S. catheters market in 2024. Triple-lumen catheters are a remarkable segment of the U.S. catheter market, mainly in areas such as central venous catheters for drug infusion and dialysis; however, they are not the dominant type. Triple-lumen catheters are recommended for their ability to do multiple functions simultaneously, like blood sampling, drug delivery, and monitoring central venous pressure.
The double-lumen segment is expected to be the fastest-growing in the U.S. catheters market during the forecast period. It is largely due to the rising prevalence of chronic diseases such as cardiovascular disorders and kidney failure, where dual-lumen catheters are usually used for dialysis as well as infusion therapies. Dual-lumen catheters provide advantages in dialysis and infusion therapies, which makes them a preferred alternative for managing these conditions.
The urinary incontinence segment dominated the U.S. catheters market in 2024. Urinary incontinence necessitates numerous catheter solutions, including condom catheters, external catheters, and intermittent or indwelling catheters. The growing prevalence of female urinary incontinence, usually linked to menopause, childbirth, and other factors, also led to the segment's supremacy. Urinary incontinence can remarkably impact a person's standard of living, leading to a raised need for effective management solutions such as catheters.
The prostatic hyperplasia general surgeries segment is expected to be the fastest growing in the U.S. catheters market during the forecast period. This growth is mainly driven by the rising prevalence of benign prostatic hyperplasia, especially in older men, and the subsequent demand for urinary catheterization to manage symptoms such as urinary retention.
The hospitals segment dominated the U.S. catheters market in 2024. Hospitals undergo a large influx of patients requiring numerous types of catheterizations for diverse medical conditions and procedures. Developments in catheter technology and the advancement of new catheter designs thus drive the need for catheters in hospitals. Many complex interventional surgeries, as well as procedures, which necessitate catheter use, are performed in hospitals.
The long-term care facilities segment is expected to be the fastest-growing in the U.S. catheters market during the forecast period. Elderly individuals and those with chronic conditions often need long-term catheterization for bladder management, contributing to increased requirements for Foley catheters as well as other indwelling catheters in long-term care facilities. Long-term care facilities are increasingly focused on infection control and patient comfort, which is boosting the acceptance of advanced catheter designs and materials, like antimicrobial coatings, to reduce complications such as catheter-associated urinary tract infections.
The U.S. catheters market is featured by a mix of specialized developers and large multinational corporations, with a strong focus on innovation and technological developments. Companies like Teleflex, Edwards Lifesciences, and others are aimed at specific niches and innovative technologies.
Abbott Laboratories (Abbott) is a medical device and healthcare company that discovers, manufactures, develops, and sells a range of products. It mainly provides gastroenterology products, cardiovascular and metabolic products, women’s health products, pain and central nervous system products, electrophysiology products, respiratory drugs and vaccines, heart failure-related products, structural heart products, vascular products, and neuromodulation products, among others.
Teleflex Inc. (Teleflex) is engaged in the program, development, production, and distribution of disposable medical technology goods utilized in critical care and surgery. The firm’s major products include circuits, endotracheal tubes, masks and bags, pain pumps, catheters, supraglottic airways, adaptors, and connectors. Its goods find applications in fields like vascular and interventional access, anesthesia, surgery, cardiac care, emergency medicine, urology, and respiratory care.
Boston Scientific Corp (Boston Scientific) is a medical technology firm that develops, produces, and commercializes apparatus for a range of interventional medical specialties. The firm provides products in the arena of electrophysiology, gastrointestinal surgery, gastroenterology, female pelvic medicine, interventional cardiology, gynecology, interventional radiology, orthopedic surgery, neurological surgery, pain medicine, urology, pulmonology, and vascular surgery.
